-

Ensoma Announces Strategic Collaboration with Takeda to Accelerate Next-Generation In Vivo Gene Therapies

Ensoma Grants Takeda Exclusive Worldwide License to Engenious™ Vectors for as Many as Five Rare Disease Indications

Potential for $100 Million in Upfront and Preclinical Research Payments with Additional Development and Commercialization Milestone Payments and Royalties Up to $1.25 Billion

BOSTON--(BUSINESS WIRE)--Ensoma, a company that formally launched today with the mission of expanding the curative power of genomic medicine by pioneering a next-generation in vivo approach, announced it has entered into a strategic collaboration with Takeda Pharmaceutical Company Limited (“Takeda”). The agreement grants Takeda an exclusive worldwide license to Ensoma’s Engenious™ vectors for up to five rare disease indications. Takeda will make an equity investment of $10 million in Ensoma’s Series A Preferred Stock with the potential for $100 million in upfront and preclinical research payments. In total, assuming success for five programs, Ensoma is eligible to receive up to $1.25 billion from Takeda, including additional development and commercialization milestone payments and up to low double-digit royalties on net sales of each product.

“Not only are we thrilled to be formally launching Ensoma today; we are delighted to announce our partnership with Takeda, an established leader in rare disease with significant clinical expertise and a global footprint,” said Paula Soteropoulos, executive chairman of Ensoma. “In addition to this early validation of our in vivo approach, near-term access to non-dilutive funding positions Ensoma to rapidly accelerate and actualize the broader potential of our revolutionary platform to provide life-changing, curative therapies for a vast set of therapeutic applications.”

Ensoma’s Engenious vectors are designed to deliver a diverse range of gene modification technologies – including those that require a high level of packaging capacity – directly to hematopoietic stem cells (HSCs) or the various cell types that arise from these cells, such as T cells, B cells and myeloid cells, without the need for stem cell collection or prior myeloablative conditioning (e.g., chemotherapy). As a result, Ensoma’s therapies can be delivered “off-the-shelf” in settings including doctors’ offices and mobile clinics.

“The Ensoma platform offers distinct advantages over AAV and ex vivo lentiviral gene therapy approaches with the potential to overcome some of the challenges associated with first-generation technologies,” said Takeda Rare Diseases Drug Discovery Unit Head Madhu Natarajan. “Takeda continues to make focused investments in differentiated, next-generation gene therapy platforms through our network of innovative collaborators with the collective goal to deliver transformative therapies and functional cures for patients living with rare diseases.”

Under the terms of the collaboration, Takeda is granted an exclusive worldwide license to Ensoma’s Engenious vector technology platform for up to five rare genetic disease indications. Ensoma will conduct preclinical research activities for the Takeda programs, and both parties will share in responsibilities leading to submission of Investigational New Drug (IND) applications. Takeda will lead development activities thereafter.

About Ensoma

Ensoma is expanding the reach of the curative power of genomic medicine by pioneering a next-generation in vivo approach using its Engenious™ vectors. Ensoma’s vectors are designed to deliver a diverse range of gene modification technologies without the need for stem cell collection or prior myeloablative conditioning (e.g., chemotherapy). As a result, Ensoma’s therapies can be delivered as a single injection in a diverse range of settings, including outpatient and settings where access to sophisticated healthcare systems may be limited. For more information, visit www.ensoma.com.

Contacts

Katie Engleman, 1AB
katie@1abmedia.com

Ensoma


Release Summary
Ensoma announces strategic collaboration with Takeda to accelerate next-generation in vivo gene therapies in rare disease indications.
Release Versions

Contacts

Katie Engleman, 1AB
katie@1abmedia.com

Social Media Profiles
More News From Ensoma

Ensoma Announces FDA Clearance of IND Application for First In Vivo HSC-Directed Gene Insertion Therapy

BOSTON--(BUSINESS WIRE)--Ensoma, a genomic medicines company advancing the future of medicine through one-time, in vivo therapies, today announced U.S. Food and Drug Administration (FDA) clearance of the Investigational New Drug (IND) application for its lead program EN-374 in X-linked chronic granulomatous disease (X-CGD), a rare and severe genetic disorder. EN-374 is a first-in-class in vivo hematopoietic stem cell (HSC)-directed therapy for X-CGD, which is caused by mutations in the CYBB gen...

Ensoma to Present Preclinical Data and Manufacturing Advancements for In Vivo HSC Engineering Platform to Treat Cancer, Immune Disorders and Genetic Diseases at ASGCT 28th Annual Meeting

BOSTON--(BUSINESS WIRE)--Ensoma will present preclinical data and manufacturing advancements at the ASGCT 28th Annual Meeting, hosted May 13-17 in New Orleans....

Ensoma Receives Rare Pediatric Disease and Orphan Drug Designations for EN-374 for Treatment of Chronic Granulomatous Disease

BOSTON--(BUSINESS WIRE)--Ensoma has received rare pediatric disease and orphan drug designations from the FDA for EN-374 for the treatment of X-CGD....
Back to Newsroom